Risk of infection associated with targeted therapies for solid organ and hematological malignancies

Inhibidors de punts de control; Everolimus; Ibrutinib

Detalhes bibliográficos
Autores: Ruiz Camps, Isabel, Aguilar-Company, Juan
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/6653
Acesso em linha:https://hdl.handle.net/11351/6653
http://hdl.handle.net/11351/6653
Access Level:acceso abierto
Palavra-chave:Medicaments antineoplàstics
Hematologia oncològica
DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Hematologic Neoplasms
Other subheadings::Other subheadings::/therapy
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
Other subheadings::Other subheadings::Other subheadings::/adverse effects
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::neoplasias hematológicas
Otros calificadores::Otros calificadores::/terapia
id ES_5922b1342bc64410c1908fde5e6f6a13
oai_identifier_str oai:recercat.cat:11351/6653
network_acronym_str ES
network_name_str España
repository_id_str
spelling Risk of infection associated with targeted therapies for solid organ and hematological malignanciesRuiz Camps, IsabelAguilar-Company, JuanMedicaments antineoplàsticsHematologia oncològicaDISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Hematologic NeoplasmsOther subheadings::Other subheadings::/therapyCHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic AgentsOther subheadings::Other subheadings::Other subheadings::/adverse effectsCOMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicosOtros calificadores::Otros calificadores::Otros calificadores::/efectos adversosENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::neoplasias hematológicasOtros calificadores::Otros calificadores::/terapiaInhibidors de punts de control; Everolimus; IbrutinibInhibidores de puntos de control; Everolimus; IbrutinibCheckpoint inhibitors; Everolimus; IbrutinibHigher risks of infection are associated with some targeted drugs used to treat solid organ and hematological malignancies, and an individual patient’s risk of infection is strongly influenced by underlying diseases and concomitant or prior treatments. This review focuses on risk levels and specific suggestions for management, analyzing groups of agents associated with a significant effect on the risk of infection. Due to limited clinical experience and ongoing advances in these therapies, recommendations may be revised in the near future. Bruton tyrosine kinase (BTK) inhibitors are associated with a higher rate of infections, including invasive fungal infection, especially in the first months of treatment and in patients with advanced, pretreated disease. Phosphatidylinositol 3-kinase (PI3K) inhibitors are associated with an increased risk of Pneumocystis pneumonia and cytomegalovirus (CMV) reactivation. Venetoclax is associated with cytopenias, respiratory infections, and fever and neutropenia. Janus kinase (JAK) inhibitors may predispose patients to opportunistic and fungal infections; need for prophylaxis should be assessed on an individual basis. Mammalian target of rapamycin (mTOR) inhibitors have been linked to a higher risk of general and opportunistic infections. Breakpoint cluster region-Abelson (BCR-ABL) inhibitors are associated with neutropenia, especially over the first months of treatment. Anti-CD20 agents may cause defects in the adaptative immune response, hypogammaglobulinemia, neutropenia, and hepatitis B reactivation. Alemtuzumab is associated with profound and long-lasting immunosuppression; screening is recommended for latent infections and prevention strategies against CMV, herpesvirus, and Pneumocystis infections. Checkpoint inhibitors (CIs) may cause immune-related adverse events for which prolonged treatment with corticosteroids is needed: prophylaxis against Pneumocystis is recommended.The authors received no financial support for the research, authorship, and/or publication of this article.SAGE PublicationsInstitut Català de la Salut[Ruiz-Camps I] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Aguilar-Company J] Servei de Malalties Infeccioses; Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202120212021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/6653http://hdl.handle.net/11351/6653Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésTherapeutic advances in infectious disease;8https://doi.org/10.1177/2049936121989548Attribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/66532026-05-29T05:05:01Z
dc.title.none.fl_str_mv Risk of infection associated with targeted therapies for solid organ and hematological malignancies
title Risk of infection associated with targeted therapies for solid organ and hematological malignancies
spellingShingle Risk of infection associated with targeted therapies for solid organ and hematological malignancies
Ruiz Camps, Isabel
Medicaments antineoplàstics
Hematologia oncològica
DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Hematologic Neoplasms
Other subheadings::Other subheadings::/therapy
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
Other subheadings::Other subheadings::Other subheadings::/adverse effects
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::neoplasias hematológicas
Otros calificadores::Otros calificadores::/terapia
title_short Risk of infection associated with targeted therapies for solid organ and hematological malignancies
title_full Risk of infection associated with targeted therapies for solid organ and hematological malignancies
title_fullStr Risk of infection associated with targeted therapies for solid organ and hematological malignancies
title_full_unstemmed Risk of infection associated with targeted therapies for solid organ and hematological malignancies
title_sort Risk of infection associated with targeted therapies for solid organ and hematological malignancies
dc.creator.none.fl_str_mv Ruiz Camps, Isabel
Aguilar-Company, Juan
author Ruiz Camps, Isabel
author_facet Ruiz Camps, Isabel
Aguilar-Company, Juan
author_role author
author2 Aguilar-Company, Juan
author2_role author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Ruiz-Camps I] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Aguilar-Company J] Servei de Malalties Infeccioses; Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Medicaments antineoplàstics
Hematologia oncològica
DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Hematologic Neoplasms
Other subheadings::Other subheadings::/therapy
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
Other subheadings::Other subheadings::Other subheadings::/adverse effects
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::neoplasias hematológicas
Otros calificadores::Otros calificadores::/terapia
topic Medicaments antineoplàstics
Hematologia oncològica
DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Hematologic Neoplasms
Other subheadings::Other subheadings::/therapy
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
Other subheadings::Other subheadings::Other subheadings::/adverse effects
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::neoplasias hematológicas
Otros calificadores::Otros calificadores::/terapia
description Inhibidors de punts de control; Everolimus; Ibrutinib
publishDate 2021
dc.date.none.fl_str_mv 2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/6653
http://hdl.handle.net/11351/6653
url https://hdl.handle.net/11351/6653
http://hdl.handle.net/11351/6653
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Therapeutic advances in infectious disease;8
https://doi.org/10.1177/2049936121989548
dc.rights.none.fl_str_mv Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408592672587776
score 15,811543

Registos relacionados